Description
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 8
Primary Industries
- Medical
- Device
- Therapeutic
- Drugs
- Disease
- Pharmaceuticals
- Scientific & Technical Instruments
IPSCIO Report Record List
Below you will find the records curated into this collection. This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs. The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms. For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report
IPSCIO Record ID: 26559
The Urgent PC Neuromodulation System uses percutaneous tibial nerve stimulation (PTNS) to treat overactive bladder and associated symptoms of urinary urgency, urinary frequency and urge incontinence.
The Urgent PC neuromodulation system is a minimally invasive device designed for office-based treatment of overactive bladder symptoms of urge incontinence, urinary urgency and urinary frequency. This product uses percutaneous tibial nerve stimulation to deliver an electrical pulse that travels to the sacral nerve plexus, a control center for bladder function.
IPSCIO Record ID: 4554
The intellectual property relates to the PoNSTM device. The Patent Rights include one XYZ claim and 22 method claims, which cover a device in the form of a mouth piece that non-invasively delivers neurostimulation to the brain stem via the trigeminal nerve.
The intellectual property relating to the PoNSTM device is the subject of U.S. Patent Application 12/348301 and Provisional Patent Application 61/019,061. (Information on the patent applications was not available from the U.S. Patent and Trademark office.)
The device is held lightly in place by the lips and teeth around the neck of the tab that goes into the mouth and rests on the anterior, superior part of the tongue. The paddle-shaped tab of the device has a hexagonally patterned array of 143 gold-plated circular electrodes (1.50 mm diameter, on 2.34 mm centers) that is created by a photolithographic process used to make printed circuit boards. It uses low-level electrical current to stimulate the lingual branch projections of at least two cranial nerves in the anterior tongue through the gold-plated electrodes.
The brain's ability to recognize its operation in response to new information sources, new functional needs, or new communication pathways is referred to as neuroplasticity. Neuroplasticity is a process underlying all cerebral learning, training, and rehabilitation. Neuromodulation is the use of external tactile stimulation to intentionally change and regulate the internal electrochemical environment of the brain. Traditional rehabilitation interventions have typically involved medication and various forms of therapies, including physical therapy. The PoNSTM device is being investigated in combination with physical therapy for the treatment of neurological symptoms from disease and trauma including traumatic brain injury (TBI) and Multiple Sclerosis. The patent is pending on the device.
IPSCIO Record ID: 245891
The Product means a controlled or extended-release oral formulation of Compound for the treatment of overactive bladder and/or urinary incontinence that requires a prescription from a physician or other health care professional in the Licensees Territory, that is intended to be administered once a day, and which but for the license granted herein, cannot be manufactured, used or sold without infringing a Valid Claim which is contained in a SANCTURA XR Patent or utilizes the Intellectual Property.
Trademark means the trademark SANCTURA XRâ„¢ and any related trademark, symbol, logo trade dress and/or trade name that Licensor may adopt and register for use in the promotion of Product.
SANCTURA XR Patents include Compositions of Quaternary Ammonium Compounds containing Bioavailability Enhancers, and, Sustained Release of Positively Charged Pharmacologically Active Molecules from a matrix containing Polymers with Polarized Oxygen Atoms, and, Once Daily Dosage forms of Trospium.
SANCTURA XR® is a muscarinic antagonist indicated for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency, and urinary frequency.
IPSCIO Record ID: 26598
– an exclusive right and license in the Field, with the right to grant sublicenses, under the Licensor Intellectual Property, to use, import, offer for sale, and Promote Products in the Territory;
– an exclusive right and license in the Field, with the right to grant sublicenses, under the Licensor Intellectual Property, to sell and distribute Products in the Territory;
– effective on the Processing Assumption Date, an exclusive right and license under the Licensor Intellectual Property, to make and have made Trospium Once Daily for use in the Field in the Territory; and
– during the Co-promotion Period and any period of time thereafter that Licensee has Promotional Materials that were printed prior to the end of the Copromotion Period and that contain the Licensor Logo, an exclusive, even as to Licensor, right and license in the Field in the Territory, with the right to grant sublicenses, to use the Licensor Logo on the Promotional Materials.
Finished Product means Trospium Twice-Daily or Trospium OnceDaily, as applicable, in its finished, labeled and packaged form, ready for distribution in the Field in the Territory.
Trademark(s) means the SANCTURA trademarks, owned by Esprit, and all related domain names and other trademark related rights, and/or any other trademark that either Party may apply to register in the Territory if such alternate trademark is selected for use in the Promotion of a Product in the Field by the Parties under this Agreement.
Sanctura® is use for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Sanctura, a quarternary ammonium compound, belongs to a class of anticholinergic compounds known as muscarinic receptor antagonists. These compounds relax smooth muscle tissue found in the bladder, thus decreasing bladder contractions. Overactive or unstable detrusor muscle function is believed to be the cause of OAB.
IPSCIO Record ID: 372635
Cyberonics Patents
5,188,104 Treatment of Eating Disorders by Nerve Stimulation
5,231,988 Treatment of Endocrine Disorders by Nerve Stimulation
5,263,480 Treatment of Eating Disorders by Nerve Stimulation
5,540,730 Treatment of Motility Disorders by Nerve Stimulation
5,540,734 Cranial Nerve Stimulation Treatments Using Neurocybernetic Prosthesis
5,707,400 Treating Refractory Hypertension by Nerve Stimulation
20060247719 Weight Loss Method and Device
20060247721 Identification of Electrodes for Nerve Stimulation in the Treatment of Eating Disorders
20060247722 Noninvasively Adjustable Gastric Band
20070027483 Stimulating Cranial Nerve to Treat Disorders Associated with the Thyroid Gland
20070027484 Autonomic Nerve Stimulation to Treat a Pancreatic Disorder
20070027492 Autonomic Nerve Stimulation to Treat a Gastrointestinal Disorder
20070027498 Selective Nerve Stimulation for the Treatment of Eating Disorders
20070093870 Cranial Nerve Stimulation to Treat Eating Disorders
Roslin Patents
6,587,719 Treatment of Obesity by Bilateral Vagus Nerve Stimulation
6,609,025 Treatment of Obesity by Sub-Diaphragmatic Nerve Stimulation
7,299,091 Treatment of Obesity by Bilateral Vagus Nerve Stimulation
20040039427 Treatment of Obesity by Sub-Diaphragmatic Nerve Stimulation
“Field of Use†shall mean the treatment (including therapeutic or diagnostic) by means of a device that applies electrical signals directly or indirectly to the vagus, trigeminal or glossopharyngeal nerves i) for weight reduction, or ii) for hypertension or diabetes (including impaired fasting glycaemia, impaired glucose tolerance or insulin resistance) in patients having a body mass index of 25 or more.
IPSCIO Record ID: 194179
The PoNSâ„¢ device is an electrical pulse generator that delivers controlled electrical stimulation to the tongue, which alters cranial nerve activity in order to intentionally change and regulate the electrochemical environment of the brain in a process called neuromodulation. When combined with physical or cognitive rehabilitation, we believe that the neuromodulation induced by PoNSâ„¢ therapy enhances neuroplasticity, or the brain’s ability to reorganize its operation in response to new information sources, new functional needs, or new communication pathways, and may benefit patients experiencing balance and gait disorders or other movement and sensory challenges associated with neurologic diseases and disorders including traumatic brain injury (“TBIâ€), multiple sclerosis (“MSâ€), cerebral palsy (“CPâ€), stroke and Parkinson’s disease.
IPSCIO Record ID: 5891
IPSCIO Record ID: 4527
The device is held lightly in place by the lips and teeth around the neck of the tab that goes into the mouth and rests on the anterior, superior part of the tongue. The paddle-shaped tab of the device has a hexagonally patterned array of 143 gold-plated circular electrodes (1.50 mm diameter, on 2.34 mm centers) that is created by a photolithographic process used to make printed circuit boards. It uses low-level electrical current to stimulate the lingual branch projections of at least two cranial nerves in the anterior tongue through the gold-plated electrodes.
The brain's ability to recognize its operation in response to new information sources, new functional needs, or new communication pathways is referred to as neuroplasticity. Neuroplasticity is a process underlying all cerebral learning, training, and rehabilitation. Neuromodulation is the use of external tactile stimulation to intentionally change and regulate the internal electrochemical environment of the brain. Traditional rehabilitation interventions have typically involved medication and various forms of therapies, including physical therapy. The PoNSTM device is being investigated in combination with physical therapy for the treatment of neurological symptoms from disease and trauma including traumatic brain injury (TBI) and Multiple Sclerosis. The patent is pending on the device.
